Apnimed

Lawrence Miller is not afraid of giants. The CEO of sleep apnea-focused Apnimed believes that even though Eli Lilly’s Zepbound (tirzepatide) recently won approval for treating moderate-to-severe obstr

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Menarini, SciClone Will Partner On

Major Japanese pharma companies' results for the fiscal second quarter ended 30 September showed generally positive trends, with Chugai Pharmaceutical Co., Ltd. , Daiichi Sankyo Co., Ltd. and Shio